Schönborn, Ines: Der Einfluß von Ovulationshemmern auf die Tumorbiologie und die Prognose des Mammakarzinoms



Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K : "Prognostic factors after 5years follow-up in female breast cancer. " Oncology 49 (1992) 93-98

Aaltomaa S, Lipponen P, Papinaho S, Syrjänen K : "Proliferating-cell nuclear antigen (PC10) immunolabeling and other proliferation indices as prognostic factors in breast cancer." J Cancer Clin Oncol 119 (1993) 288-294

Adami HO, Malker B, Holmberg L, Persson I, Stone B ": The relation between survival and age at diagnosis in breast cancer." N Engl J Med 315 (1986) 559-563

Ahmed S, Tartter PI, Jothy S, Brower ST, Bratton J : "The prognostic significance of previous benign breast disease for women with carcinoma of the breast" . J Am Coll Surg 183 (1996) 101-104

Alexieva-Figusch J, van Putten WLJ, Blankenstein MA, Blonk-van der Wijst J, Klijn JGM ": The prognostice value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer." Cancer 61 (1988) 758-768

Al-Idrissi HY, Ibrahim EM, Kurashi NY, Sowayan SA : "Breast cancer in a low-risk population. The influence of age and menstrual status on disease pattern and survival in Saudi Arabia" . Int J Cancer 52 (1992) 48-51

Anderson TJ, Battersby S, King RBJ, McPherson K, Going JJ ": Oral contraceptive use influences resting breast proliferation" . Human Path 20 (1989 ) 1139-1144

Anderson TJ, Ferguson DJP, Raab GM: "Cell turnover in the „ resting“ human breast: influence of parity, contraceptive pill, age and laterality" . Br J Cancer 46 (1982 ) 376-382

Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KPH, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D, Toronto Breast Cancer Study Group : "C-erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer" . J Clin Oncol 16 (1998) 1340-1349

Antoniotti S, Taverna D, Sapei ML, Hynes NE, De Bortoli M ": Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms" . Br J Cancer 70 (1994) 1095-1101

Arriagada R, Rutqvist LE, Skoog L, Johansson H, Kramar A : "Prognostic factors and natural history in lymph node-negative breast cancer patients." Breast Cancer Res Treat 21 (1992) 101-109

Astrow AB : "Timing of breast cancer surgery, nodes, hormones and retrospectoscopy" . Lancet 343 (1994) 1517-1518

Auvinen A, Elovianio L, Hakama M ": Breast self-examination and survival from breast cancer" . Breast Cancer Res Treat 38 (1996) 161-168

Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE, Rubens RD, Fentiman IS: "Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer" . Lancet 337 (1991) 1261-1264

Baptista J, Pike M ": Exact confidence limits for the odds-ratio in a two by two table" . Appl Stat 26 (1977) 214-220

Bargmann CI, Hung MC, Weinberg RA ": The neu oncogene encodes an epidermal growth factor receptor-related protein" . Nature 319 (1986) 226-229

Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR : "Immunhistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?" Hum Pathol 24 (1993 ) 469-476

Bässler R : "Pathologie der Brustdrüse" . In: Spezielle Pathologische Anatomie . Hrsg.: Doerr W, Uehlinger E, Seifert G, Vol 11 Berlin-Heidelberg-New York: Springer 1978

Bässler R, Bocker W, Hermanek P, Pickartz H, Prechtel K, Schauer A, Schnurch HG, Stegner HE : "Die gegenwärtige Situation des Gradings beim Mammakarzinom" . Pathologe 13 (1992) 130-134

Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS : "Expression of transforming growth factor (and its messenger ribonucleic acid in human breast cancer: Its regulation by estrogen and its possible significance" . Mol Endocrinol 2 (1988 ) 543-555


Battersby S, Anderson TJ ": Histological changes in breast tissue that characterize recent pregnancy" . Histopathology 15 (1989 ) 415-419

Battersby S, Robertson BJ, Anderson TJ, King RJB, McPherson K : "Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast" . Br J Cancer 65 (1992) 601-607

Beckmann MW, Niederacher D, Massenkeil G, Tutschek B, Beckmann A, Schenko G, Schnurch HG, Bender HG : "Expression analyses of epidermal growth factor receptor and HER-2/neu: No advantage of prediction of recurrence or survival in breast cancer" . Oncology 53 (1996) 441-447

Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G : "Mortality associated with oral contraceptive use: 25 year follow up cohort of 46000 women from Royal College of General Practitioners‘ oral contraception study" . BMJ 318 (1999) 96-100

Beral V, Reeves G, Bull D, Peto R ": Comment, Collaborative Group on Hormonal Factors in Breast Cancer" . Lancet 348 (1996) 683

Berg JW, Hutter VP : "Breast Cancer" . Cancer 75 (1995) 257-269

Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB ": Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy" . Am J Epidemiol 130 (1989 ) 221-228

Bernoux A, de Cremoux P, Lainé-Bidron C, Martin EC, Asselain B, Magdelénat H : "Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome" . Breast Cancer Res Treat 49 (1998 ) 219-225

Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN : "Management of breast cancer during pregnancy using a standardized protocol." J Clin Oncol 17 (1999 ) 855-861

Bertheau Ph, Steinberg SM, Merino MJ ": C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: Immunohistochemical analysis and clinicopathologic correlation" . Hum Pathol 29 (1998) 323-329

Bianchi S, Calzolari A, Vezzosi V, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S ": Lack of prognostic value of p53 protein expression in node-negative breast cancer" . Tumori 83 (1997 ) 669-672

Bianco AR, Mastro LD, Gallo C, Perrone F, Matano E, Pagliarulo C, De Placido S : "Prognostic role of amenorrhoe induced by adjuvant chemotherapy in premenopausal patients with early breast cancer." Br J Cancer 63 (1991) 799-803

Bines J, Oleske DM, Cobleigh MA : "Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer" . J Clin Oncol 14 (1996) 1718-1729

Black M, Hankey BF, Barclay THC : "Parity as a prognostic factor in young breast cancer patients." J Natl Cancer Inst 70 (1983) 27-30

Black WC, Bordin GM, Varsa EW, Herman D ": Histologic comparison of mammary carcinomas among a population of southwestern American Indian, Spanish American and Anglo women" . Am J Clin Pathol 71 (1978) 142-145

Bloom HJG, Richardson WW ": Histological grading and prognosis of breast cancer. A study of 1409 cases opf which 359 have been followed for 15 years." Br J Cancer 11 (1957) 359-377

Bonnier P, Romain S, Giacalcone PL, Laffargue F, Martin PM, Piana L : "Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy" . Obstet Gynecol 85 (1995) 11-17

Bosari, S., A.K.C. Lee, G. Viale, G.J. Heatley, G. Coggi ": Abnormal p53 immonoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up" . Virchows Archiv A Pathol. Anat. 421 (1992) 291-295

Bradbury JM, Arno J, Edwards AW : "Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland" . Oncogene 8 (1993) 1551-1558

Brocklehurst D, Wilde CE, Finbow JAH, Brett R, Champion AE, Dewhurst DG : "Relative importance of estrogen and progesterone receptor assays as prognostic indicators in primary breast cancer: a short-term study." Clin Chem 35 (1989 ) 238-240

Bulbrook RD, Swain MC, Wang DY, Hayward JL, Kumaoka S, Takatani O, Abe O, Utsunomiya J ": Breast cancer in Britain and Japan: Plasma oestradiol-17beta, Oestrone and "


"Progesterone, and their urinary metabolites in normal British and Japanese women."

Eur J Cancer 12 (1976 ) 725-735

Bulbrook RD, Thomas BS : "Hormones are ambiguous risk factors for breast cancer."

Acta Oncol 28 (1989) 841-847

Carter CL, Allen C, Henson DE ": Relation of tumor size, lymph node status and survival in 24.740 breast cancer cases." Cancer 63 (1989) 181-187

Catherino WH, Jeng MH, Jordan VC: "Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism." Br J Cancer 67 (1993) 945-952

Chang KJ, Lee TTY, Linares-Gruz G, Fournier S, de Ligniéres B : "Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. " Fertil Steril 63 (1995) 785-791

Chang S, Hulka BS, Baird DD, Ingle JN, Newman B, Graham ML 2nd, Qaqish B, Donohue JH, Melton LJ 3rd: "Breast cancer survival and the timing of tumor removal during the menstrual cycle." Cancer Epidemiol Biomarkers Prev 6 (1997) 881-886

Chapman JW, Murray D, McCready, Hanna W, Kahn HJ, Lickley HLA, Trudeau ME, Mobbs BG, Sawka CA, Fish EB, Pritchard KI: "An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer?" Eur J Cancer 32A (1996) 1949-1956

Chevallier B, Heintzmann F, Mosseri V, Dauce JP, Bastit Ph, Graic Y, Brunelle Ph, Basuyau JP, Comoz M, Asselain B: "Prognostic value of estrogen and progesteron receptors in operable breast cancer." Cancer 62 (1988) 2517-2524

Chilvers CED, Deacon JM: "Oral contraceptives and breast cancer." Br J Cancer 61 (1990) 1-4

Chrysogelos SA, Ronit IY, Lauber AH, Murphy JM ": Mechanisms of EGF receptor regulation in breast cancer cells." Breast Cancer Res Treat 31 (1994) 227-236

Clark GM, Sledge GW, Osborne CK, McGuire WL: "Survival from first recurrence: relative importance of prognostic factors in 1.015 breast cancer patients."

J Clin Oncol 5 (1987 ) 55-61

Clark GM, McGuire WL: "The clinical usefulness of estrogen-receptor and other markers of hormone dependence" . Proc Royal Soc Edinburgh 95B (1989) 145-150

Clark GM: "Do we really need prognostic factors for breast cancer" ? Breast Cancer Res Treat 30 (1994) 117-126

Clarke CL and Sutherland RL: "Progestin regulation of cellular proliferation." Endocrine Rev 11 (1990) 266-301

Cobleigh MA, Norlock FE, Oleske DM, Starr A ": Hormone replacement therapy and high S phase in breast cancer." JAMA 281 (1999) 1528-1530

Cole PT : "Oral contraceptives and breast neoplasia." Cancer 39 (1977) 1906-1908

Coletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB: "The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta." J Clin Invest 87 (1991) 227-238

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: "Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies." Lancet 347 (1996) 1713-1727

Collett K, Skjarven, Mahle BO: "The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index" . Breast Cancer Res Treat 48 (1998) 1-9

Cooper JA, Rohan TE, Cant ELMcK, Horsfall DJ, Tilley WD: "Risk factors for breast cancer by estrogen receptor status: a population-based case-control study" . Br J Cancer 59 (1998) 119-125

Cordell JL, Falini B, Erber WN, Ghosh AK; Abdulaziz Z, Macdonald S, Pulford KAF, Stein H, Mason DY: "Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phospatase (APAAP-complexes)." J Histochem Cytochem 32 (1984) 219-229

Correa P, Johnson WD: "International variation in the histology of breast carcinoma" . UICC Techn Rep Series 35 (1978) 36-65

Cowley BD, Chadwick LJ, Grantham JJ, Calvet JP: "Sequential protooncogene expression in regenerating kidney following acute renal injury." J Biol Chem 264 (1989 ) 8389-8393

Cox DR ": Regression models and life tables." J R Stat Soc 34 (1972) 137-220


Cullen KJ, Lippman ME: "Estrogen regulation of protein synthesis and cell growth in human breast cancer." Vitamins and Hormones 45 (1989) 127-172

Dalton LW, Page DL, Dupont WD ": Histologic grading of breast carcinoma. "

"A reproducibility study." Cancer 73 (1994) 2765-2770

Darbre PhD, King RJB: "Progression to steroid insensitivity can occur irrespective of the presence of functional steroid receptors." Cell 51 (1987) 521-528

Dati C, Antoniotti S, Taverna D, Perroteau I, DeBortoli M: "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells" . Oncogene 5 (1990) 1001-1006

De Bortoli M, Dati C, Antoniotti S, Maggiora P, Sapei ML: "Hormonal regulation of "

"c-erbB-2 oncogene expression in breast cancer cells." J Steroid Biochem Molec Biol 43 (1992) 21-25

De Potter CR, Schelfhout AM: "The neu-protein and breast cancer" . Virchows Arch 426 (1995) 107-115

Di Fronzo G, Coradini D, Cappeletti V, Miodini P, Granata G, Schwartz M, Panko WB : "Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. " Anticancer Res 10 (1990) 1699-1706

Di Lieto A, De Rosa G, Albano G, Pagnano AM, Campanile M, Terracciano L, Pontillo M, Cimmino E, Covelli A, Paladini A: "Desogestrel versus Gestodene in oral contraceptives: Influence on the clinical and histomorphological features of benign breast disease. " Eur J Obstet Gynecol 55 (1994) 71-83

Dickson RB, McManaway ME, Lippman ME ": Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth." Science 32 (1986a) 1540-1543

Dickson RB, Huff KK, Spencer EM, Lippman ME ": Induction of epidermal growth factor-related polypeptides by 17beta-estradiol in MCF-7 human breast cancer cells" . Endocrinology 118 (1986b) 138-142

Dickson RB, Lippman ME: "Estrogen regulation of growth and polypeptide growth factor secretion in human breast carcinoma." Endocrine Rev: 8 (1986) 29-43

Dickson RB, Lippman ME: "Growth factors in breast cancer" . Endocrine Rev 16 (1995) 559-589

Dittadi R, Donisi PM, Brazzale A, Cappellozza L, Bruscagnin G, Gion M: "Epidermal growth factor receptor in breast cancer. Comparison with non-malignant breast tissue." Br J Cancer 67 (1993) 7-9

Donegan WL, Perez-Meza EM: "Lobular carcinoma - an indication for elective biopsy of the second breast." Amer Surg 176 (1972) 178-185

Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A, Campbell WS, Franz C, Kahle L, Taylor PR: "Relationships of age and reproductive characteristics with plasma estrogens and androgens in premenopausal women." Cancer Epidemiol Biomarkers Prev 4 (1995) 381-386

Dougall WC, Qian X, Creene MI : "Interaction of the Neu/p185 and EGF-R tyrosine kinasees: implications for cellular transformation and tumor therapy. " J Cell Biochem 53 (1993 ) 61-73

Ebeling K, Ray R, Nischan P, Thomas DB, Kunde D, Stalsberg H: "Combined oral contraceptives containing chlormadinone acetate and breast cancer: results of a case-control study" . Br J Cancer 63 (1991) 804-808

Eissa S, Khalifa A, el Gharib A, Salah N, Mohamed MK: "Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short- term prognosis in breast cancer." Anticancer Res 17 (1997) 3091-3097

Elledge RM, Allred DC : "The p53 tumor suppressor gene in breast cancer. (Review" ). Breast Cancer Res Treat 32 (1994) 39-47

Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL ": Prognostic significance of p53 gene alterations in node-negative breast cancer" . Breast Cancer Res Treat 26 (1993) 225-235

Elledge RM, Allred DC : "Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer " Res Treat 52 (1998) 79-98

Elwood JM, Godolphin W: "Oestrogen receptors in breast tumours: association with age, menopausal status and epidemiological and clinical features in 735 patients" . Br J Cancer 42 (1980) 635-644

Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SAW, Osborne CK: "Measurement of steroid hormone receptors in breast cancer patients on tamoxifen" . Breast Cancer Res


Treat 26 (1993) 237-246

Ewertz M, Gillander S, Meyer L, Zedeler K: "Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer" . Int J Cancer 49 (1991) 526-530

Fechner RE ": Breast cancer during oral contraceptive therapy." Cancer 26 (1970)


Fentiman IS, Gregory WM, Richards MA ": Effect of menstrual phase on surgical treatment of breast cancer. Comment." Lancet 344 (1994) 402

Fentiman IS, Gregory WM: "The hormonal milieu and prognosis in operable breast cancer" . Cancer Surveys 18 (1993) 149-163

Fernandez-Pol JA: "Modulation of EGF-Receptor protooncogene expression by growth factors and hormones in human breast carcinoma cells." Oncogenesis 2 (1991) 173-185

Fisher ER, Taylor M: "Changing patterns of some pathologic parameters of mammary carcinomas." Cancer 32 (1973) 1380-1391

Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E: "Presence of growth stimulating factor in serum following primary tumour removal in mice." Cancer Res 49 (1989) 1996-2001

Fisher ER, Anderson S, Redmond C, Fisher B: "Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06. " Cancer 71 (1993) 2507-2514

Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR : "Problems with p53 immunhistochemical staining: the effect of fixation and variation in the methods of evaluation." Br J Cancer 69 (1994) 26-31

Fournier von D, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V: "Growth rate of 147 mammary carcinomas" . Cancer 45 (1980) 2198-2207

Fournier von D, Abel U, Spratt JA, Anton HW: "Wachstumsgeschwindigkeit des Mammakarzinoms, Bedeutung für Früherkennung und Therapieeffekte." Geburtshilfe-Frauenheilkd 54 (1994) 286-290

Fowble B, Hanlon AL, Patchefsky A, Freedman G, Hoffman JP, Sigurdson ER, Goldstein LJ: "The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation" . Int J Radiat Oncol Biol Phys 42 (1998) 105-115

Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL: "The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients" . Breast Cancer Res Treat 29 (1994) 41-49

Freiss G, Prébois C, Vignon F: "Control of breast cancer cell growth by steroids and growth factors: Interactions and mechanisms" . Breast Cancer Res Treat 27 (1993) 47-68

Fuqua SAW, Hill StM, Chamness GC, Benedix MG,Greene GL, O‘Malley BW, McGuire WL: "Progesteron receptor gene restriction fragment length polymorphisms in human breast tumors" . J Natl Cancer Inst 83 (1991) 1157-1160

Fuqua SAW ": Abnormalities of the estrogen receptor in breast cancer - introduction." Breast Cancer Res Treat 26 (1993) 117-118

Galea MH, Blamey RW, Elston CE, Ellis IO : "The Nottingham Prognostic Index in primary breast cancer." Breast Cancer Res Treat 22 (1992) 207-219

Gapstur SM, Morrow M, Sellers TA: "Hormone replacement therapy and risk of breast cancer with a favorable histology." JAMA 281 (1999) 2091-2097

Gasparini, G., P. Bevilacqua, F. Pozza, S. Meli, P. Boracchi, E. Marubini, J.R.C. Sainsbury : "Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer" . Br J Cancer (1992) 970- 976

Gasparini G, Boracchi P, Verderio P, Bevilacqua ,P: "Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry" . Int J Cancer 57 (1993) 822-829

Gasparini G, Boracchi P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N: "A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma." Breast Cancer Res Treat 29 (1994a) 59-71

Gasparini G, Gullick WJ, Maluta S, Palma PD, Caffo O, Leonardi E, Boracchi P, Pozza F, Lemoine NR, Bevilacqua P : "C-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma - an immunocytochemical study." Eur J Cancer 30A (1994b) 16-22

Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T ": Prognostic significance of p53, angiogenesis, and other conventional features in "


"operable breast cancer: subanalysis in node-positive and node-negative patients" . Int J Oncol 12 (1998) 1117-1125

Gelber RD, Goldhirsch A ": Menstrual effect on surgical cure of breast cancer" . Lancet II (1989) 1343-1344

Ghahary A, Murphy LJ: "Uterine insulin-like growth factor-I receptors: regulation by estrogen and variation throughout the oestrous cycle" . Endocrinology 125 (1989) 597-604

GIVIO (Interdisciplinary Group for Cancer Care Evaluation "): Oestrogen receptor status and risk factors for breast cancer." Oncology 45 (1988) 303-307

Glass K, Hoover RN ": Rising incidence of breast cancer: relationship to stage and receptor status." J Natl Cancer Inst 82 (1990 ) 693-696

Goldhirsch A, Gelber RD, Castiglione M, O‘Neill A, Thurlimann B, Rudenstam CM, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey MF, Pagani O, Price K, Senn HJ: "Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI" . Ann Oncol 8 (1997) 751-756

Gompel A, Martin A, Simon P, Plu-Bureau G, Hugol D, Audouin J, Leygue E, Truc JB, Poitout Ph ": Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle" . Breast Cancer Res Treat 38 (1996) 227-235

Granata G, Coradini D, Cappelletti V, Fronzo GD ": Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers" . Eur J Cancer 27 (1991) 970-972

Grant ECG, Antony HM, Myhill S, Price EH, Steel CM: "Breast cancer and hormone exposure" . Lancet 348 (1996) 682

Greenberg ER, Vessey MP, McPherson K, Doll R, Yeates D: "Body size and survival in premenopausal breast cancer" . Br J Cancer 51 (1985) 691-697

Guinee VF, Olsson H, Moller T, Hess KR, Taylor SH, Fahey T, Gladikov JV, van den Blink JW, Bonichon F, Dische S, Yares JW, Cleton FJ ": Effect of pregnancy on prognosis for young women with breast cancer" . Lancet 343 (1994) 1587-1589

Gullick WJ ": Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers" . British Med Bulletin 47 (1991a) 87-98

Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG ": C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes." Br J Cancer 63 (1991b) 434-438

Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S: "Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy." Proc Natl Acad Sci USA 96 (1999) 2520-2525

Hackenberg R, Hawighorst Th, Filmer A, Huschmand N, Schulz KD ": Medroxyprogesterone acetate inhibits the proliferation of estrogen-and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor" . Breast Cancer Re Treat 25 (1993 ) 217-224

Haerslev T, Jacobson GK, Zedeler K ": Proliferating cell nuclear antigen (PCNA) and "

"c-erbB-2 oncoprotein in breast carcinoma with correlations to histopathological parameters and prognosis" . Oncology Reports 2 (1995) 99-105

Haerslev T, Jacobson GK, Zedeler K ": Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas" . Breast Cancer Res Treat 37 (1996) 101-113

Hall PA, Levison PA, Woods AL, Yu CC, Kellock DB, Watkins JA,Barnes DM, Gillett CE, Camplejohn R, Dover R: "Proliferating cell nuclear antigen (PCNA) immunolocalisation in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms." J Pathol 162 (1990) 285-294

Hanna W, Schneider M: "Enhancement of tumour metastasis and suppression of natural killer cell activity by beta-oestradiol treatment." J Immunol 130 (1982) 974-980

Hargreaves DF, Knox F, Swindell R, Potten CS, Bundred NJ ": Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy." Br J Cancer 78 (1998) 945-949

Harlap S, Zauber AG, Pollack DM, Tang J, Arena AE, Sternfels P, Borgen P, Norton L : "Survival of premenopausal women with breast carcinoma. Effects of menstrual timing of surgery" . Cancer 83 (1998) 76-88


Harris JR, Lippman ME, Veronesi U, Wilett W: "Breast cancer." N Engl J Med 327 (1992) 319-328

Hartmann LC, Sebo TJ, Kamel NA, Podratz KC, Cha SS, Wieand HS, Keeney GL, Roche PC : "Proliferating Cell Nuclear Antigen in epithelial ovarian cancer: relation to results at second look laparotomy and survival." Gynecol Oncol 47 (1992) 191-195

Hawkins RA, Tesdale AL, Killen ME, Jack WJL, Chetty U, Dixon JM, Hulme MJ, Prescott RJ, McInttyre MA, Miller WR: "Prospective evaluation of prognostic factors in operable breast cancer." Br J Cancer 74 (1996) 1469-1478

Hemminki E : "Oral contraceptives and breast cancer" . Br Med J 313 (1996) 63-64

Hilsenbeck SG, Ravdin PM, Moor CA, Chamness GC, Osborne CK, Clark GM: "Time-dependence of hazard ratios for prognostic factors in primary breast cancer" . Breast Cancer Res Treat 52 (1998) 227-237

Holmberg L, Ekbom A, Calle E, Mokdad A, Byers T ": Breast cancer mortality in relation to self-reported use of breast self-examination. A cohort study of 450.000 women" . Breast Cancer Res Treat 43 (1994) 137-140

Horwitz KB ": Mechanisms of hormone resistance in breast cancer." Breast Cancer Res Treat 26 (1993) 119-130

Howell A, Dodwell DJ, Anderson H, Redford J: "Response after withdrawal of tamoxifen and progestogens in advanced breast cancer" . Ann Oncol 3 (1992) 611-617

Hrushesky WJM, Bluming AZ, Gruber SA, Sothern RB ": Menstrual influence on surgical cure of breast cancer." Lancet II (1989) 9949-952

Hsieh CC, Crosson AW, Walker AM, Trapido EJ, Mac-Mahon B: "Oral contraceptive use and fibrocystic breast disease of different histological classifications." J Natl Cancer Inst 72 (1984) 285-292

Hulka BS, Chambless LE, Wilkinson WE, Deubner DC, McCarty KS Sr, McCarty KS Jr: "Hormonal and personal effects on estrogen receptors in breast cancer" . Am J Epidemol 119 (1984) 692-704

Hulman G, Trowbridge P, Taylor CN, Chilvers CED, Sloane JP, "UK National Case-Control Study Group: Oral contraceptive use and histopathology of cancerous breasts in young women" . J Pathol 167 (1992) 407-411

Hurd C, Khattree N, Alban P, Nag K, Jhanwar SC, Dinda S, Moudgil VK ": Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line" . J Biol Chem 270 (1995) 28507-28510

Hurd C, Khattree N, Dinda S, Alban P, Moudgil VK ": Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells." Oncogene 15 (1997) 991-995

Hurd C, Dinda S, Khattree N, Moudgil VK ": Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells." Oncogene 18 (1999) 1067-1072

Hynes NE : "Amplification and overexpression of the c-erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor and potential as a target for cancer therapy" . Semin Cancer Biol 4 (1993) 19-26

Inano H, Suzuki K, Onoda M, Kobayashi H, Wakabayashi K: "Comparative effect of chlormadinone acetate and diethylstilbestrol as promoters in mammary tumorigenesis of rats irradiated with gamma-rays during lactation" . Breast Cancer Res Treat 53 (1999) 153-160

Jatoi I : "Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis" . Breast Cancer Res Treat 52 (1998) 217-225

Jeng MH, Jordan VC: "Growth stimulation and differential regulation of transforming growth factor-ß1 (TGFß1), TGFß2, and TGFß3 messenger RNA levels by Norethindrone in MCF-7 human breast cancer cells" . Molec Endocrin 5 (1991 ) 1120-1128

Jeng MH, Parker CJ, Jordan VC: "Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation" . Cancer Res 52 (1992) 6359-6546

Jordan VC: "A therapeutic withdrawal can make a strategic advance" . Ann Oncol 3 (1992) 587-588

Jordan VC, Jeng MH, Catherino WH, Parker CJ ": The estrogenic activity of synthetic progestins used in oral contraceptives. " Cancer 71 (1993) 1501-1505

Juret P, Couette JE, Mandard AM, Carre A, Delozier T, Brune D, Vernhes JC ": Age at menarche as a prognostic factor in human breast cancer." Eur J Cancer 12 (1976) 701-704

Kaelin WG: J Natl "The emerging p53 gene family. Review" .Cancer Inst 91 (1999 ) 594-598


Kaplan EL, Meier P ": Nonparametric estimation from incomplete observations." J Am Stat Assoc 53 (1958) 457-481

Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: "Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cacer cells grown in the short-term and in the long-term absence of estrogens" . Cancer Res 47 (1987) 4355-4360

Kay CR, Hannaford PC ": Breast cancer and the pill - a further report from the Royal College of General Practitioners‘ oral contraception study" . Br J Cancer 58 (1988) 675-680

Kelsey JL, Gammon MD, John EM ": Reproductive factors and breast canc" er. Epidemiol Rev 15 (1993) 36-47

King RJB: "Biology of female sex hormone action in relation to contraceptive agents and neoplasia" . Contraception 43 (1991) 527-542

King RJB: "Estrogen and progestin effects in human breast carcinogenesis" . Breast Cancer Res Treat 27 (1993) 3-15

Kleist S von ": Prognostic factors in breast cancer: Theoretical and clinical aspects (review)." Anticancer Res 16 (1996 ) 3907-3912

Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA : "The clinical significance of epiermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. " Endocrine Rev 13 (1992 ) 3-17

Klijn JGM, Look MP, Portengen H, Alexieva-Figusch J, van Putten WLJ, Foekens JA: "The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study." Breast Cancer Res Treat 29 (1994) 73-83

Kloosterboer HJ, Schoonen WGEJ, Deckers GH, Klijn JGM ": Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. " J Steroid Biochem Molec Biol 49 (1994) 311-318

Koga M, Musgrove EA, Sutherland RL ": Modulation of hte growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene in human breast cancer cells by epidermal growth factor and insulin" . Cancer Res 49 (1989) 112 -116

Kordon EC, Molinolo AA, Pasqualini CD, Charreau EH, Pazos P, Dran G, Lanari C: "Progesterone induction of mammary carcinomas in BALB/c female mice." Breast Cancer Res Treat 28 (1993) 29-39

Korzeniowski St, Dyba St: "Reproductive history and prognosis in patients with operable breast cancer" . Cancer 74 (1994) 1591-1594

Koscielny S, Tubiana M, Valleron AJ: "A simulation model of the natural history of human breast cancer" . Br J Cancer 52 (1985) 515-524

Kristen P, Müller JG, Caffier H: "Prognostic relevance of p53 in node negative breast cancer" . Anticancer Res 17 (1997) 2869-2871

Kroman N, Wohlfahrt J Mouridsen HT, Westergaard T, Melbye M : "Time since childbirth and prognosis in primary breast cancer: population based study." Br Med J 315 (1997) 851-853

Kroman N, Wohlfahrt J, West Andersen K, Mouridsen HT, Westergaard T, Melbye M: Parity, "age at first childbirth and the prognosis of primary breast cancer" . Br J Cancer 78 (1998) 1529-1533

Kronqvist P, Montironi R, Collan YU, Bartels PH, Thompson D: "Management of uncertainty in breast cancer grading with Bayesian belief networks" . Anal Quant Cytol Histol 17 (1995) 300-308

Kronqvist P, Montironi R, Kuopio T, Collan YU ": Subjective breast cancer grading. Analysis of reproducibility after application of Bayesian belief networks" . Anal Quant Cytol Histol 19 (1997) 423-429

Kurebayashi J, Sonoo H, Shimozuma K: "Timing of surgery in relation to the menstrual cycle and its influence on the survival of Japanese women with operable breast cancer" . Surg Today 25 (1995) 519-524

Kuttenn F, Mouffarege A, Mauvais-Jarvis P ": The hormonal basis of discontinuous progestational contraception." Nouv Presse Med 7 (1978) 3109-3113

Lakhani SR ": The transition from hyperplasia to invasive carcinoma of the breast. Review article." J Pathol 187 (1999) 272-278

Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO ": Transient increase in the risk of breast cancer after giving birth. " N Engl J Med 331 (1994) 5-9


Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM: "Induction of protooncogene JUN/AP-1 by serum in TPA" . Nature 334 (1988) 629-631

Lees AW, Jenkins HJ, May CL, Cherian G, Lam EWH, Hanson J ": Risk factors and 10-year breast cancer survival in northern Alberta" . Breast Cancer Res Treat 13 (1989) 143-151

Lehrer ST, Levine E, Savoretti P, Cropley J, Botstein Ch, Kyung Song H, Mandell L, Shank B: "Past pregnancy is associated with axillary node involvement in women with breast cancer" . Cancer 69 (1992) 981-983

Leinster SJ : "Impact of molecular biology on the clinical management of breast cancer" . Biochem Soc Symp 63 (1998) 185-191

Lemon HM, Rodriguez-Sierra JF ": Timing of breast cancer surgery during the luteal menstrual phase may improve prognosis" . Nebr Med J 81 (1996) 73-78

Lemon HM, Rodriguez-Sierra JF: "Ethnic differences in estrogen metabolism in healthy women. (letter) " J Natl Cancer Inst 89 (1997) 1626-1628

Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, Dalla Palma P, Barbareschi M ": PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables" . J Clin Pathol 45 (1992) 416-419

Lesser ML, Rosen PP, Senie RT, Duthie K, Menendez-Botet CJ, Schwartz MK: "Estrogen and progesteron receptors in breast carcinoma: correlations with epidemiology and pathology." Cancer 48 (1981) 299-309

Levesque MA, Katsaros D, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis EP ": Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients" . Int J Cancer 79 (1998) 147-152

Levine AJ: "P53, the cellular gatekeeper for growth and division" . Cell 88 (1997) 323-331

Lippman ME, Dickson RB, Bates S, Knabbe C, Huff K, Swain S, McManaway M, Bronzert D, Kasid A, Gelmann EP: "Autocrine and paracrine growth regulation in human breast cancer" . Breast Cancer Res Treat 7 (1986 ) 59 -70

Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Marin S, Syrjänen K: "The changing importance of prognostic factors in breast cancer during long-term follow-up" . Int J Cancer 51 (1992) 698-702

Longrace TA; Bartow SA ": A correlative morphologic study of human breast and endometrium in the menstrual cycle" . Am J Surg Path 10 (1986) 382-393

Lonn U, Lonn S, Nilsson B, Stenkvist B ": Prognostic significance of c-erbB-2 amplification in fine-needle biopsies of breast cancer patients not operated at diagnosis" . Breast Cancer Res Treat 39 (1996) 213-220

Low SC, Galea MH, Blamey RW: "Timing breast cancer surgery" . Lancet 338 (1991) 691

Lupu R, Lippman M ": The role of erbB2 signal transduction pathways in human breast cancer" . Breast Cancer Res Treat 27 (1993) 83-93

Luthy IA, Bégin DJ, Labrie F ": Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogo) cells in culture." J Steroid Biochem 31 (1988) 845-852

Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I ": Prognostic characteristics in breast cancers after hormone replacement therapy" . Breast Cancer Res Treat 38 (1996) 325-334

Manni A, Wright C, Badger B, Bartholomew M, Herlyn M, Mendelsohn J, Masui H, Demers L: "Role of transforming growth factor-alpha-related peptides in the autocrine/paracrine control of experimetnal breast cancer growth in vitro by estradiol, prolactin and progesteron." Breast Cancer Res Treat 15 (1990) 73-83

Marcus JN, Watson P, Page DL, Lynch HT ": Pathology and heredity of breast cancer in young women" . Mongr Natl Cancer Inst 16 (1994) 23-34

Markopoulos C, Berger U; Wilson P, Gazet JC, Coombes RC: "Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle" . BMJ 296 (1988) 1349-1351

Marth C, Lang T, Cronauer MV, Doppler W, Zeimet AG, Bachmair F, Ullrich A, Daxenbichler M ": Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells." Int J Cancer 52 (1992) 311-316

Martinez V, Azzopardi JG: "Invasive lobular carcinoma of the breast: incidence and variations" . Histopathol 3 (1979) 467-488

Matthews PN, Millis RR, Hayward JL ": Breast cancer in women who have taken contraceptive "


"steroids." Br med J 282 (1981) 774-776

Mauvais-Jarvis P, Kuttenn F, Gompel A : "Antiestrogen action of progesterone in breast tissue" . Hormone Res 28 (1987) 212-218

McCann AH, Dervan PA, O‘Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: "Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer" . Cancer Res 51 (1991 ) 3296-3303

McCredie M, Paul Ch, Skegg DCG, Williams S ": Reproductive factors and breast cancer in New Zealand." Int J Cancer 76 (1998) 182-188

McCulloch P, Choy A: "Effect of menstrual phase on surgical treatment of breast cancer" . Lancet 344 (1994) 402-403

McGuire WL: "The optimal timing of mastectomy: low tide or high tide?" Ann Intern Med 115 (1991) 401-403

McKinlay SM , Brambilla DJ, Posner JG": The normal menopause transition" . Maturitas 14 (1992) 103-115

McMahon B, List ND, Eisenberg H: "Relationship of survival of breast cancer patients to parity and menopausal status. In: " Forrest APM, Kunkler PB" (eds) " Prognostic Factors in Breast Cancer "," Williams and Wilkins , Baltimore , (1968) 5

McMahon B: "Reproduction and breast cancer of the breast" . Cancer 71 (1993) 3185-3188

McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M ": Early oral contraceptive use and breast cancer: Results of another case-conrol study" . Br J Cancer 56 (1987) 653-660

McTiernan A, Thomas DB, Johnson LK, Rosemann D : "Risk-factors for estrogen receptor-poor breast cancers" . J Natl Cancer Inst 77 (1986) 849-854

Medlock KL, Lyttle CR, Kelepouris N, Neman ED, Sheehan DM ": Estradiol down-regulation of the rat uterine estrogen receptor." Proc Soc Exp Biol Med 196 (1991 ) 293-300

Mehta RR, Beattie CW , "Das Gupta TK: Endocrine profile in breast cancer patients receiving chemotherapy." Breast Cancer Res Treat 20 (1991) 125-132

Merchant WJ, Millis RR, Smith P, Chaudary MA, Barnes DM ": Expression of c-erbB2 and p53 protein is similar in breast cancer from British and Japanese women." Int J Cancer 84 (1999) 278-283

Millard FC, Bliss JM, Chilvers CED, Gazet JC: "Oral contraceptives and survival in breast cancer." Br J Cancer 56 (1987) 377-378

Miller AB, Howe GR, Sherman GJ, Lindsay JP, Yatle MF, Dinner PJ, Risch HA, Preston DL : "Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis." N Engl J Med 321 (1989a) 1285-1289

Miller N, McPherson K, Jones L, Vessey M: "Histopathology of breast cancer in young women in relation to use of oral contraceptives" . J Clin Pathol 42 (1989b) 387-390

Minckwitz G von, Grischke EM, Kaufmann M ": Effect of menstrual phase on surgical treatment of breast cancer. Comment" . Lancet 344 (1994) 403

Mohammed SN, Smith P, Hodgson SV, Fentiman IS, Miles DW, Barnes DM, Millis RR, Rubens RD: "Family history and survival in premenopausal breast cancer" . Br J Cancer 77 (1998 ) 2252-2256

Mohle-Boetani J, Grosser S, Malee M, Whitemore AS: "Survival advantage among patients with breast cancer diagnosed at 45-49 years of age. Letter" . N Engl J Med 315 (1986) 587

Mohle-Boetani JC, Grosser S, Whittemore AS, Malec M, Kampert JB, Pfaffenberger RS ": Body size, reproductive factors and breast cancer survival." Prev Med 17 (1988) 634-642

Molina R, J J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM: "c-erbB-2 oncoprotein, CEA, and CA15.3 in patients with breast cancer: prognostic value" . Breast Cancer Res Treat 51 (1998) 109-119

Möller P, Mechtersheimer G, Kaufmann M, Moldenhauer G, Momburg F, Mattfeldt T, Otto HF: "Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast" . Virchows Archiv A Pathol Anat 414 (1989) 157-164

Mondini G, Decian F, Sorice G, Friedman D, Spirito C, Costantini M, Sormani MP, Crivalleri D: "Timing of surgery related to menstrual cycle and prognosis of premenopausal women with breast cancer" . Anticancer Res 17 (1997) 787-190

Montesco MC, Zavagno G, Meggiolaro F, Frizzera E, Mainente P, Rupolo M, Lise M: "Vimentin and proliferating cell nuclear antigen (PCNA) expression in node-negative breast carcinomas and their correlations with pathologic variables and prognosis." Breast 4 (1995) 175-178


Moolgavkar SH, Day NE, Stevens RG: "Two stage model for carcinogenesis: epidemiology for breast cancer in females" . J Natl Cancer Inst 65 (1980) 559-569

Morrison AS, Lowe CR, Macmahon B, Warram JW Jr, Yuasa S ": Survival of breast cancer patients related to incidence risk factors" . Int J Cancer 9 (1972) 470-476

Moyer DL, Sahwi SE, MacCaulay: "Cells of uterine fluid. In: Beller FK, Schumacher GFB, eds. Amsterdam: " Elsevier North Holland (1979): 59-71

Mukku VR, Stancel G : "Regulation of epidermal growth factor receptor by estrogen" . J Biol Biochem 260 (1985) 9820-9824

Murphy LJ, Sutherland RL, Stead B, Murphy LC, Laganes L ": Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells." Cancer Res 46 (1986) 728-734

Murray PA, Barrett-Lee P, Travers M, Luqumani Y, Powles T, Coombes RC: "The prognostic significance of transforming growth factors in breast cancer" . Br J Cancer 67 (1993) 1408-1412

Musey VC, Collins DC, Musey PI, Martino-Saltzman D, Preedy JRK: "Long term effects of a first pregnancy on the secretion of prolactin" . N Engl J Med 316 (1987) 229-234

Musgrove EA, Lee CSL, Sutherland RL ": Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor-alpha, epidermal growth factor receptor, c-fos, and c-myc genes" . Mol Cell Biol 11 (1991) 5032-5043

Nair KM, Sankaranarayanan R, Nair SK, Amma NS, Varghese C, Padmakumari G, Cherian T: "Overall survival from breast cancer in Kerala, India in relation to menstrual, reproductive and clinical factors" . Cancer 71 (1993) 1791-1796

Nandi S, Guzman RC, Yang J ": Hormones and mammary carcinogenesis in mice, rats, and humans: A unifying hypothesis" . Proc Natl Acad Sci 92 (1995) 3650-3657

Narita T, Funahashi H, Satoh Y, Takagi H: "Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis" . Jap J Clin Oncol 23 (1993) 20-25

Nayak, BK, Baral RN, "Das BR: P53 gene mutation in relation to p53 protein accumulation in male and female breast cancer" . Neoplasma 43 (1996) 305-310

Nettleton J, Long J, Kuban D, Wu R, Shaeffer J, El-Mahdi A: "Breast cancer during pregnancy: quantifying the risk of treatment delay" . Obstet Gynecol 87 (1996) 414-418

Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL ": Epidermal Growth Factor receptor (EGFr); results of a 6 year follow-up study in " operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 63 (1991) 146-150

Nigro JM, Baker JS, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner St, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Harris CC, Vogelstein B: "Mutations in the p53 gene occur in diverse human tumor types." Nature 342 (1989) 705-708

NIH Consensus Conference ": Treatment of early-stage breast cancer" . JAMA 265 (1991) 391-398

Nischan P, Ebeling K, Thomas DB, Hirsch U: "Comparison of recalled and validated oral contraceptive histories." Am J Epidemiol 138 (1993) 697-703

Nischan P, Ebeling K ": Oral contraceptive containing chlormadinone acetate and cancer incidence at selected sites in the German Democratic Republic. A correlation analysis." Int J Cancer 34 (1984) 671-674

Noguchi M, Thomas M, Kitagawa H, Kinoshita K, Miyazaki I, Mizukami Y ": PCNA-expression and Ag-NOR score in breast cancer: correlation with clinicopathologic variables and patient survival." Int J Oncol 2 (1993) 265-269

NomuraY, Kobayashi S, Takatani O, Sugano H, Matsumoto K, McGuire WL: "Estrogen receptor and endocrine responsivness in Japanese versus American breast cance patients" . Cancer Res 37 (1977) 106-110

Nomura Y, Shirouzu M, Takayama T: "Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status" . Breast Cancer Res Treat 49 (1998 ) 51-60

Norberg T, Jansson T, Sjögren S, Matensson C, Andreasson I, Fjällskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J ": Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53" . Acta Oncol 35 Suppl 5 (1996) 96-102


O‘Reilly SM, Barnes RS, Camplejohn RS, Bartkoua J, Gregory WM, Richards MA: "The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer" . Br J Cancer 63 (1991) 444-446

Oliver DJ, Ingram DM : "Timing of surgery during the menstrual cycle for breast cancer: Possible role of growth factors" . European J Cancer 31 (1995) 325-328

Olsson H, Ranstam "J: Breast cancer and the pill" . Br J Cancer 59 (1989) 834

Olsson H: "Reproductive events, occuring in adolescence at the time of development of reproductive organs and at the time of tumour initiation, have a bearing on growth characteristics and reproductive hormone regulation in normal and tumour tissue investigated decades later - a hypothesis" . Med Hypothesis 28 (1989) 93-97

Olsson H, Ranstam J, Baldetorp B, Ewers SB, Fernö M, Killander D, Sigurdsson H: "Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions" . Cancer 67 (1991a) 1285-1290

Olsson H, Borg A, Fernö M, Ranstam J, Sigurdsson H: "Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones." J Natl Cancer Inst 83 (1991b) 1483-1487

Olsson H, Jernstrom H, Alm P, Kreipe H, Ingvar C, Jonsson PE, Ryden S: "Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use and reproductive factors" . Breast Cancer Res Treat 40 (1996) 187-196

Orr RK, Fraher KM: "Parity is associated with axillary nodal involvement in operable breast cancer." Breast Cancer Res Treat 34 (1995) 71-76

Osborne MP, Rosen PP, Lesser ML, Schwartz MK, Menendez-Botet CJ, Fishman JH, Kinne FW, Beattie EJ ": The relationship between family history, exposure to exogenous hormones, and estrogen receptor protein in breast cancer." Cancer 51 (1983) 2134-2138

Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SAW, Ramasharme K, Marshall M, Li CH ": Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor." Mol Endocrinol 3 (1989) 1701-1709

Padmanabhan N, Howell A, Rubens RD: "Mechanism of action of adjuvant chemotherapy in early breast cancer" . Lancet II (1986) 411-414

Pagani O, O‘Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thurlimann B, Simoncini E, Fey M, Price K, Senn HJ ": Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI" . Eur J Cancer 34 (1998) 632-640

Page DL, Dupont WD, Rogers LW, Rados MS: "Atypical hyperplastic lesions of the female breast." Cancer 55 (1985) 2698-2708

Pastides H, Kelsey J, LiVolsi VA, Holford TR, Fischer DB, Goldenberg IS: "Oral contraceptive use and fibrocystic breast disease with special reference to its histopathology" . J Natl Cancer Inst 71 (1983) 5-9

Pater MM, Hughes GA, Hyslop DE, Nakshatu H, Pater A: "Glucocorticoid dependent oncogenic transformation by type 16 but not type II human papilloma virus DNA." Nature 335 (1988) 832-835

Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y: "Isolation of the neu/HER-2 stimulatory ligand: a 44kd glycoprotein that induces differentiation of mammary tumor cells" . Cell 69 (1992) 205-216

Perren TJ: "c-erbB-2 oncogene as a prognostic marker in breast cancer." Br J Cancer 63 (1991) 328-332

Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: "Design and analysis of clincal trials requiring prolonged observation of each patient. II. Analysis and examples." Br J Cancer 35 (1977) 1-39

Petrakis NL, Wrensch MR, Ernster VL, Miike R, Murai J, Simberg N, Siiteri PK: "Influence of pregnancy and lactation on serum and breast fluid estrogen levels: implication for breast cancer risk" . Int J Cancer 40 (1987) 587-591

Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP, Aaronson SA: "Oncogenic potential of c-erbB-2 in human mammary epithelial cells" . Oncogene 6 (1991) 1189-1194

Pietras RJ, Arboleda J, Wongvipat N, Ramos L, Sliwkowski MX, Slamon DJ: "HER-2/neu "


"signaling regulates estrogen receptor in breast cancer." Proc Ann Meet Am Assoc Cancer Res 36 (1995) A 1516

Pike MC, Henderson BE, Krailo MD, Duke A, Roy S: "Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use." Lancet II (1983a) 926-930

Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: "’Hormonal‘ risk factors, ’breast tissue age‘ and the age-incidence of breast cancer." Nature 303 (1983b) 767-770

Pink JJ, Jordan VC: "Models of Estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines" . Cancer Res 56 (1996) 2321-2330

Pirinen R, Lipponen P, Syrjanen K: "Expression of epidermal growth factor receptor (EGFR) in breast canceer as related to clinical, prognostic and cytometric factors." Anticancer Res 15 (1995) 2835-2840

Plu-Bureau G, Lê MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P: "Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease" . Br J Cancer 70 (1994) 270-277

Possinger K, Wischnewski M, Schönborn I, Lichtenegger W ": What can we do with prognostic and predictive factors in breast cancer" ? Educational Book, 21st ESMO Congress (1996) 3-9

Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A: "The effect of age and menstrual cycle upon proliferative activity of the normal human breast" . Br J Cancer 58 (1988) 163-170

Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: "Progesterone and estrogen receptors and mammary neoplasia in the IOWA Women‘s Health Study: How many kinds of breast cancer are there?" Cancer Epidemiol Biomark Prev 4 (1995) 319-326

Poulin R, Baker D, Poirier D, Labrie F: "Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: An in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids" . Breast Cancer Res Treat 17 (1990) 197-210

Powles J, Smith IE: "Medical management of breast cancer." Lancet 338 (1991) 620

Pratap R, Shousha S: "Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status" . Breast Cancer Res Treat 49 (1998) 35-39

Press MF, Cordon-Cardo C, Slamon DJ: "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues" . Oncogene 5 (1990) 953-962

Prioleau J, Schnitt SJ: "P53 antigen loss in stored paraffin slides." New Engl J Med 332 (1995) 1521-1522

Prives C, Hall PA : "The p53 pathway. " J Pathol 187 (1999) 112-126

Prost-Avalet O, Oursin J, Adessi GL: "In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma." J Steroid Biochem Molec Biol 39 (1991) 967-973

Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet Ph, Grenier J: "Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause" . Cancer 83 (1998) 698-705

Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM ": Rising levels of estrogen receptor in breast cancer over 2 decades" . Cancer 74 (1994) 1601-1606

Quenel N, Wafflart J, Bonichon F, De Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: "The prognostic value of c-erbB-2 in primary breast carcinomas: A study on 942 cases." Breast Cancer Res Treat 35 (1995) 283-291

Querzoli P, Albonico G, Ferretti St, Rinaldi R, Beccati D, Corcione St, Indelli M, Nenci I: "Modulation of biomarkers in minimal breast carcinoma" . Cancer 83 (1998) 89-97

Ranstam J, Olsson H, Garne JP, Aspegren K, Janzon L: Survival "in breast cancer and age at start of oral contraceptive usage" . Anticancer Res 11 (1991) 2043-2046

Ratajczak HV, Sthern RB, Hrushesky WJM: "Estrous influence on surgical cure of mouse breast cancer." J Exp Med 168 (1988) 88-96

Read LD, Keith D, Slamon DJ, Katzenellenbogen BS: "Hormonal modulation of HER-2/neu protooncogen messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines" . Cancer Res 50 (1990) 3947-3951


Reed MJ, Ross MS, Lai LC, Ghilchik MW, James T ": In vivo conversion of norethisterone to ethinyloestradiol in perimenopausal women" . J Steroid Biochem 37 (1990) 301-303

Reese DM, Slamon DJ: "HER-2/neu signal transduction in human breast and ovarian cancer." Stem Cells 15 (1997) 1-8

Reid SE, Murthy MS, Kaufman M, Scanlon EF: "Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer" . Br J Surg 83 (1996) 1037-1046

Révillion F, Bonneterre J, Peyrat JP: "ErbB2 oncogene in human breast cancer and ist clinical significance." Eur J Cancer 34 (1998) 791-808

Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD ": The influence on survival of delay in the presentation and treatment of symptomatic breast cancer" . Br J Cancer 79 (1999) 858-864

Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP ": P53 mutations in colorectal cancer" . Proc Natl Acad Sci USA 87 (1990) 7555-7559

Rohan TE, Hartwick W, Miller AB, Kandel RA ": Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk" . J Natl Cancer Inst 90 (1998) 1262-1269

Rohan TE, Miller AB ": A cohort study of oral contraceptive use and risk of benign breast disease" . Int J Cancer 82 (1999) 191-196

Romieu I, Willet WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE: "Prospective study of oral contraceptive use and risk of breast cancer in women" . J Natl Cancer Inst 81 (1989) 1313-1321

Rosen PP, Ashikari R, Thaler H, Ishikawa S, Hirota T, Abe O, Yamamoto H, Beattie EJ, Urban JA, Mike V ": A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan and New York, USA." Cancer 39 (1977) 429-434

Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L ": Immunohistochemical detection of HER2/neu in patients with axillary lymph node-negative breast carcinoma" . Cancer 75 (1995a) 1320-1326

Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: "P53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis" . J Clin Oncol 13 (1995b) 821-831

Rosner D, Lane WW, Brett RP: "Influence of oral contraceptives on the prognosis of breast cancer in young women" . Cancer 55 (1985) 1556-1562

Rosner DH, Lane WW ": Oral contraceptive use has no adverse effect on the prognosis of breast cancer" . Cancer 57 (1986) 591-596

Rosner DH, Lane WW: "Predicting recurrence in axillary-node negative breast cancer patients" . Breast Cancer Res Treat 25 (1993) 127-139

Royal College of General Practitioners ". Breast cancer and oral contraceptives: Findings in Royal College of General Practitioners study." Br Med J 282 (1981) 2089-2092

Rozengurt E, Sinnett-Smith J, Taylor-Papadimitriou J ": Production of PDGF-like growth factor by breast cancer cell lines" . Int J Cancer 36 (1985) 246-252

Russell KS, Hung MC ": Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor" . Cancer Res 52 (1992) 6624-6629

Russo J, Russo IH ": Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis" . Cancer Res 40 (1980) 2677-2687

Russo J, Tay LK, Russo IH: "Differentiation of the mammary gland and susceptibility to carcinogenesis." Breast Cancer Res Treat 2 (1981) 5-73

Russo IH, Gimotty P, Dupuis M, Russo J ": Effect of medroxyprogesterone acetate on the response of the rat mammary gland to carcinogenesis" . Br J Cancer 59 (1989) 210-216

Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ: "Biology of disease: Comparative study of human and rat mammary tumorigenesis." Lab Invest 62 (1990) 244-278

Russo J, Russo I: "Hormonally induced differentiation: a novel approach to breast cancer prevention." J Cell Biochem Suppl 22 (1995) 58-64

Rutteman GR ": Contraceptive steroids and the mammary gland: Is there a hazard? - Insights from animal studies." Breast Cancer Res Treat 23 (1992) 29-41

Sauerbrei W, Blettner M, Schmoor C, Bojar H, Schumacher M for the German Breast Cancer Study Group ": The effect of oral contraceptive use on the prognosis of node-positive breast cancer patients" . Eur J Cancer 34 (1998) 1348-1351


Sauerbrei W, Royston P, Schmoor C, Schumacher M and the Germann Breast Cancer Study Group (GBSG "): Modelling the effects of standard prognostic factors in node-positive breast cancer" . Br J Cancer 79 (1999) 1752-1760

Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN: "Estrogen replacement therapy and breast cancer survival in a large screening study" . J Natl Cancer Inst 91 (1999) 264-270

Schindler AE ": Gestageneinwirkung an der Brust - protektiv oder proliferativ?" Zentralbl Gynakol 119 (1997) 359-365

Schlesselman JJ, Stadel BV, Korper M, Yu W, Wingo PA ": Breast cancer detection in relation to oral contraception" . J Clin Epidemiol 45 (1992 ) 449-459

Schmidt-Gollwitzer K, Schönegg W, Scheiber A, Wessel J: "Ovarialfunktion und Rezidiv bei adjuvanter Chemotherapie des Mammakarzinoms." Geburtsh u Frauenheilk 47 (1987) 695-699

Schmitt FC, Pereira EM, Andrade LM, Torresan M, de Lucca L ": The proliferating cell nuclear antigen index in breast carcinomas does not correlate with mitotic index and estrogen receptor immunoreactivity" . Pathol Res Pract 190 (1994) 786-791

Schneider HP, Jackisch C: "Potential benefits of estrogens and progestogens on breast cancer." Int J Fertil Womens Med 43 (1998) 278-285

Schönborn I, Nischan P, Ebeling K: "Oral contraceptive use and the prognosis of breast cancer" . Breast Cancer Res Treat 30 (1994) 283-292

Schönborn I, Zschiesche W, Minguillon C, Spitzer E, Möhner M, Ebeling K, "Grosse R: Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer." Cancer Res Clin Oncol 121 (1995) 115-122

Schoonen WGEJ, Joosten JWH, Kloosterboer HJ: "Effects of two classes of progestagens, Pregnane and 19-Nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines." J Steroid Biochem Molec Biol 55 (1995) 423-437

Schoultz E von, Cline M, Sahlin L, Isaksson E, Skoog L: "Sex steroid receptors, IGF-1 mRNA and proliferation in breast tissue during hormonal treatment. " Breast Cancer Res Treat 50 (1998) 301

Schouten LJ, Hupperets PSGJ, Jager JJ, Volovics L, Wils JA, Verbeek ALM, Blijham GH: "Prognostic significance of etiological risk factors in early breast " cancer. Breast Cancer Res Treat 43 (1997) 217-223

Schroeter CA, De Potter CR, Rathsmann K, Willighagen RGJ, Greep JC: "c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis." Br J Cancer 66 (1992) 728-734

Schuchard M, Landers JP, Sandhu NP, Spelsberg "TC: Steroid hormone regulation of nuclear proto-oncogenes" . Endocr Rev 14 (1993) 659-669

Segui MA, Climent MA, Bellmunt J, Albanelli J, Fernandez M, Filella X, Jo J, Gimenez N, Iglesias E, Miralles M, Alonso C, Peiro G, Perezpicanol E, Ballesta AM: "P53 oncoprotein as a prognostic indicator in patients with breast cancer. " Anticancer Res 18 (1998) 507-511

Sekeris CE: "Hormonal steroids act as tumour promotors by modulating oncogene expression" . J Cancer Res Clin Oncol 117 (1991) 96-101

Senie RT, Rosen PP, Rhodes PR, Lesser ML ": Timing of breast cancer excision during the menstrual cycle influences duration of disease- free survival" . Ann Int Med 115 (1991) 337-342

Seshradi R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P, South Australian Breast Cancer Group ": Clinical significance of HER-2/neu oncogene amplification in primary breast cancer." J Clin Oncol 11 (1993) 1936-1942

Seshradi R, Horsfall DJ, McCaul K, Leong AS: "A simple index to predict prognosis independent of axillary node information in breast cance" r . Aust N Z J Surg 67 (1997) 765-770

Sheen CM, Eng HL, Chou FF, Chen WJ: "The prognostic significance of proliferating cell nuclear antigen in patients with lymph node-positive breast cancer" . Arch Surg 132 (1997) 264-267

Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P ": Racial disparity in the association of p53 gene alterations with breast cancer survival." Cancer Res 55 (1995) 1485-1490

Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP ": Oestrogen receptor expression in the "


"normal and pre-cancerous breast" . J Pathol 188 (1999) 237-244

Shrestha P, Yamada K, Wada T, Maeda S, Watatani M. Yasutomi M, Takagi H, Mori M: "Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer" . Virchows Archiv (A) 421 (1992) 193-202

Shupnik MA,. Gordon MS, Chin WW: "Tissue specific regulation of rat estrogen receptor mRNAs" . Mol Endocrinol 3 (1989) 660-665

Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Fernö M, Killander D, Olsson H ": Indicators of prognosis in node-negative breast cancer" . N Engl J Med 322 (1990) 1045-1053

Siitonen SM, Kallioniemi OP, Isola JJ: "Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer" . Am J Pathol 142 (1993) 1081-1089

Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P: "Axillary lymph node dissections for T1a breast carcinoma - Is it indicated? " Cancer 73 (1994) 664-667

Silvestrini, R., E. Benini, M.G. Daidone, S. Veneroni, P. Boracchi, V. Cappalletti, G. DiFronzo, U. Veronesi: "P53 as an independent prognostic marker in lymph node-negative breast cancer" . J Natl Cancer Inst 85 (1993) 965-970

Sitruk-Ware R : Progestogen use and breast cancer. 8th International Congress on the Menopause Abstraktband (1996) A21

"Sjögren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers." J Clin Oncol 16 (1998) 462-469

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc Guire WL ": Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene" . Science 235 (1987) 177-182

Slamon DJ, Clark GM ": Amplification of c-erbB-2 and aggressive human breast tumors?" Science 240 (1988) 1795-1798

Slattery ML, Berry TD, Kerber RA: "Is survival among women diagnosed with breast cancer influenced by family history of breast cancer?" Epidemiology 4 (1993) 543-548

Söderqvist G, Von Schoultz B, Tani E, Skoog L: "Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle" . Am J Obstet Gynecol 168 (1993) 874-879

Soderquist G, Olsson H, Wilking N, von Schoultz B, Carlström K ": Metabolism of estrone sulfate by normal breast tissue: influence of menopausal status and oral contraceptives" . J Steroid Biochem Molec Biol 48 (1994) 221-224

Soderquist N, Skoog G ": Breast epithelial proliferation in healthy women using oral contraception" . Breast Cancer Res Treat 50 (1998) 300

Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JT, Wold LE, Kovach JS: "Pattern of p53 gene mutations in breast cancers of women of the Midwestern United States" . J Natl Cancer Inst 84 (1992) 246-252

Spencer JD, Millis RR, Hayward JL: "Contraceptive steroids and breast cancer." Br Med J 1 (1978) 1024-1026

Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M ": Prognostic value of estrogen and progesteron receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1.262 patients" . Europ J Cancer Clin Oncol 25 (1989) 1233-1249

Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND ": Carcinoma of the breast in postmenopausal hormone user and nonuser control groups" . J Am Coll Surg 178 (1994) 167-170

Staffa JA, Newschaffer CJ, Jones JK, Miller V: " Progestins and breast cancer: an epidemiologic review. " Fertili Steril 57 (1992) 473-491

Stalsberg H, Thomas DB, Noonan EA and the WHO Collaborative Study of Neoplasia and Steroid Contraceptives: " Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors" . Int J Cancer 44 (1989) 399-409

Stanford JL, Szklo M, Boring CC, Brinton LA, Diamond EA, Greenberg RS, Hoover RN: "A case-control study of breast cancer stratified by estrogen receptor status." Am J Epidemiol 125 (1987) 184-194


Stegner HE : Gynäkologie und Geburtshilfe . Stuttgart : Enke 6. Aufl (1996) 3

Stenkvist B, Westman-Naeser S, Vegelius J, Holmquist J, Nordin B, Bengtsson E, Eriksson O: "Analysis of reproducibility of subjective grading systems for breast carcinoma" . J Clin Pathol 32 (1979) 979-985

Stewart AJ, Westley BR, May FEB: "Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen" . Br J Cancer 66 (1992) 640-648

Strickland DM, Gambrell RD, Butzin CA, Strickland K : "The relationship between breast cancer survival and prior postmenopausal estrogen use." Obstet Gynecol 80 (1992) 400-404

Sutherland RL, Hall RE, Pang GYN, Musgrove EA, Clarke CL ": Effect of medroxyprogesterone acetat on proliferation and cell cycle kinetics of human mammary carcinoma cells" . Cancer Res 48 (1988) 5084-5091

Sutherland RL, Watts CKW, Musgrove EA ": Cell cycle control by steroid hormones in breast cancer. implications for endocrine resistance." Endocrine related Cancer 2 (1995) 87-96

Swanson GM, Nawal ER, Lin CS, Hankey BF, Miller B, Horn-Ross P, White E, Liff JM, Harlan LC, McWorther WP, Mullan PB, Key CR ": Breast cancer among black and white women in the 1980s." Cance r 72 (1993) 788-798

Szarewski A, Guillebaud J: "Breast cancer and hormone exposure" . Lancet 348 (1996) 682-683

Taioli E, Garte SJ, Trachman J, Garbers S, Sepkovic DW, Osborne MP, Mehl St, Bradlow HL: "Ethnic differences in estrogen metabolism in healthy women. Letter" . J Natl Cancer Inst 88 (1996) 617

Taverna D, Antionetti S, Maggiora P, Dati C, De Bortoli M, Hynes NE: "ErbB-2 expression in estrogen receptor positive breast tumor cells is regulated by growth modulatory reagents" . Int J Cancer 56 (1994) 522-528

Thijssen JHH : "Oestrogens, progestins and breast proliferation. " Zentralbl Gynakol 119 (1997) 43-47

Thomas DB : "Do hormones cause breast cancer" . Cancer 53 (1984) 595-604

Thorpe SM, Rose C, Rasmussen BB, Mouridens H, Bayer T, Mouridsen HT, Bayer T, Keiding N, Danish Breast Cancer Coopperative Group ": Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node-negative primary breast cancer." Cancer Res 47 (1987) 6126-6133

Thorpe SM, Christensen J, Rasmussen BB, Rose C ": Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer." Eur J Cancer 29A (1993) 971-977

Toikanen SP, Kujari HP, Joensuu H: "Factors predicting late mortality from breast cancer." Br J Cancer 27 (1991) 586-591

Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ: "Adjuvant chemohormonal therapy with cyclophospamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group Trial." Cancer 65 (1990) 200-206

Treurniet HF, Rookus MA, Peterse HL, Hart AAM, Van Leeuwen FE ": Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor" . Cancer res 52 (1992) 2344-2345

UK National Case-Control Study Group ": Oral contraceptive use and breast cancer risk in young women." Lancet I (1989) 973-982

Ulm K, Jänicke F, Pache L, Danegger F ": Change in prognostic impact of uPA and PAI-1 in node-negative breast cancer patients during the follow-up" . Breast Cancer Res Treat 37 (1996) 59

Van der Burg B, Kalkhoven E, Isbrücker L, de Laat SW: "Effects of progestins on the proliferation of estrogen-dependent human breast tumor cells " under growth factor-defined conditions. J Steroid Biochem Molec Biol 42 (1992) 457-465

Van der Kooy K, Rookus MA, Peterse HL, Van Leeuwen FE ": P53-protein overexpression in relation to risk factors for breast cancer" . Am J Epidemiol 144 (1996) 924-933

Vanek VW, Kadivar TF, Bourguet CC: "Correlation of menstrual cycle at time of breast cancer surgery to disease-free and overall survival" . South Med J 90 (1997) 780-788

Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C, Giacobone A, Merson M, Pacetti G, Raselli R, Saccozzi R: "Effect of menstrual phase on surgical treatment of breast cancer." Lancet 343 (1994) 1545-1547


Vessey MP, Doll R, Jones K, Mc Pherson K, Yeates D : "An epidemiological study of oral contraceptives and breast cancer" . Br Med J 175 (1979) 1757-1960

Vessey M, Baron J, Doll R, McPherson K, Yeates D: "Oral contraceptives and breast cancer: final report of an epidemiological study" . Br J Cancer 47 (1983) 455-462

Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D: "Mortality among oral contraceptive users: 20year follow-up of women in a cohort study." Br Med J 299 (1989) 1487-1491

Vihko R, Isotalo H: "Estrogen and Progesteron receptors in breast cancer." Acta Obstet Gynecol Scand Suppl 101 (1981) 29-35

Ville Y, Lasry S, Spyratos F, Hacene K, Brunet M: "Menstrual status and breast cancer surgery." Breast Cancer Res Treat 16 (1990) 119-121

Visscher DW, Wykes S, Kubus J, Crissman JD : "Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer" . Breast Cancer Res Treat 22 (1992) 111-118

Walker R, Dearing SJ: "Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas" . Breast Cancer Res Treat 53 (1999) 167-176

Welshons WV, Jordan VC: "Adaption of estrogen-dependent MCF-7 cells to low estrogen (phenol-red free) culture." Eur J Clin Oncol 12 (1987) 1935-1939

Westhoff Cl : "Oral contraceptives and breast cancer - a resolution emerges" . Contraception 54 (1996) i-ii (3 Suppl )

WHO, "Histological typing of breast tumours" . 2nd edition WHO, Geneva 1981

WHO Collaborative Study of Neoplasia and Steroid Contraceptives ": Invasive cervical cancer and combined oral contraceptives: " Br Med J 290 (1985) 961-965

WHO Collaborative Study of Neoplasia and Steroid Contraceptives: "Breast Cancer and combined oral contraceptives: results from a multinational study" . Br J Cancer 61 (1990) 110-119

WHO Collaborative Study of Neoplasia and Steroid Contraceptives : "Breast cancer and depot-medroxyprogesterone acetate: a multinational study." Lancet 338 (1991) 833-838

Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, Potten CS : "Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast" . Int J Cancer 48 (1991) 206-210

Wingo PA, Austin J, Kosinski A, Ory HW, Schlesselman JJ, Eley W, Peterson B ": Five-year survival of women with breast cancer according to prior use of oral contraceptives. " Hormonal Carcinogenesis II , Li JJ, Li SA, Gustafsson JA, Nandi S, Sekely LI (eds), New York , Springer 1996

Wingrave JS ": Progesteron effects and their relationship to lipoprotein changes. Report on the oral contraceptive study of the Royal College of General Practitioners" . Acta Obstet Gynecol Scand 105 (1982) Suppl 33-36

Winstanley J, Cooke T, George WD, Murray G, Holt S, Croton R, Griffiths K, Nicholson R: "The long-term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast." Br J Cancer 64 (1991) 99-101

Wren BG : "Hormonal replacement therapy and breast cancer." Eur Menopause J 2 (1995) 13-19

Wyss P, Rageth JC, Unger C, Hochuli E: "Die prognostische und therapeutische Bedeutung der Steroidrezeptoren beim invasiven Mammakarzinom" . Geburtsh u Frauenheilk 52 (1992) 611-616

Yang Q, Khoury MJ, Rodriguez C, Calle EE, Tatham LM, Flanders WD ": Family history score as a predictor of breast cancer mortality: prospective data from the Cancer Prevention Study II, United States, 1982-1991." Am J Epidemiol 147 (1998) 652-659

Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N ": Insulin-like growth factor II mRNA expression in human breast cancer." Cancer Res 48 (1988) 6691-6696

Yoshimoto M, Sakamoto G, Ohashi Y ": Time dependency of the influence of prognostic factors on relapse in breast cancer" . Cancer 72 (1993) 2993-3001

Yu CC, Dublin EA, Camplejohn RS, Levison DA ": Optimization of immunistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen" . Anal Cell Pathol 9 (1995) 45-52

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.

DiML DTD Version 2.0
Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML - Version erstellt am:
Wed Jun 13 17:25:48 2001